DHEA: Enhancing Your Physical and Hormonal Health

Learn how hormonal health and DHEA influence your body functions and support your overall hormonal balance.

Abstract

In this educational post, I guide you through an integrative, evidence-based approach to hormone optimization, focusing on four tightly connected areas that commonly challenge clinicians and patients: sex hormone-binding globulin (SHBG), polycystic ovary syndrome (PCOS), prostate-specific antigen (PSA) interpretation, and dehydroepiandrosterone (DHEA). Drawing on modern research methods and leading studies, I explain how metabolic health, gut dysbiosis, inflammation, and nutrient status intersect with androgen dynamics and reproductive function. I share detailed clinical reasoning, including dosing logic for metformin and spironolactone in PCOS, stepwise strategies to manage high SHBG, why percent free PSA changes workup decisions, and how DHEA acts as a neurosteroid with independent receptor activity. Throughout, I incorporate how integrative chiropractic care enhances outcomes by improving autonomic regulation, biomechanics, and lifestyle adherence. I also include personal observations from my clinical practice and research communication channels. By the end, you will have a clear, stepwise framework for evaluating, treating, and monitoring patients with complex endocrine presentations using modern, evidence-based methods and a whole-person lens.

About the Author

I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. My clinical and research insights are available at:

• https://chiropracticscientist.com/
• https://www.linkedin.com/in/dralexjimenez/

Highlighted Section: Why an Integrative Model Matters

• I combine advanced hormone diagnostics with integrative chiropractic care, nutrition, movement, sleep, and stress physiology.
• This model improves autonomic balance, insulin sensitivity, gut motility, and pain modulation, which in turn influences hormone receptor signaling and adherence to therapeutic plans.
• The narrative below is based on years of treating patients for hormone optimization, integrating current literature and real-world outcomes.

Hormone Optimization Begins with a Systems Map

When I first started working deeply in hormone therapy, I noticed a recurring frustration: patients had “perfect” lab numbers but felt unwell. That divergence pushed me to build a clinical map with colleagues over decades. The lesson was simple but profound: hormonal symptoms are rarely explained by a single hormone alone. They emerge from a network in which thyroid function, vitamin D receptor activity, oxygen delivery, gut dysbiosis, inflammation, sleep, and stress physiology modulate receptor responsiveness and downstream effects.

A vivid example sits in everyday practice. Years ago, a patient told me, “I just don’t think these are working.” Her serum levels were in range. Symptoms were not. We agreed on one change: consistent vitamin D. Within a few months, she returned amazed—same hormone dose, different lived results. Vitamin D modulates nuclear receptor activity, immune tone, and transcriptional responses in tissues, changing how the body “hears” hormonal signals (Bolland et al., 2014; Bouillon et al., 2019). That insight is emblematic: lab ranges are snapshots; physiology is a movie.

Clinical takeaway:

• Build a systems map that includes thyroid, vitamin D, gut, metabolic health, stress/cortisol, and sleep.
• Treat the network, not just the number.

Sex Hormone-Binding Globulin: Interpreting and Working With SHBG

Key concept: SHBG binds sex steroids (notably testosterone), regulating bioavailability. Clinically, high SHBG reduces free testosterone; low SHBG often signals metabolic dysfunction.

• Physiological context:

• • High SHBG is often seen with estrogen therapy, certain medications, lower body mass, and alcohol intake. It reduces free testosterone, potentially blunting symptomatic response despite “normal” total testosterone.
  • Low SHBG correlates with insulin resistance, metabolic syndrome, and increased cardiometabolic risk (Crawford et al., 2019; Ding et al., 2009).

• Strategy:
  • Do not reflexively “lower” SHBG. Instead, manage the terrain. If SHBG is high and symptomatic:

• Consider titrating testosterone carefully to achieve receptor saturation without overshooting.
• Support hepatic function, reduce alcohol, and evaluate medication effects.
• Address thyroid status and nutritional cofactors that influence hepatic SHBG production.

• • When SHBG is low:

• Treat insulin resistance (nutrition, activity, sleep optimization; metformin or GLP-1 receptor agonists when appropriate).
• Anticipate that lower SHBG will increase free fractions; adjust dosing conservatively to avoid androgenic side effects.

• • I use targeted nutraceuticals that influence androgen metabolism and receptor sensitivity (e.g., diindolylmethane/DIM, shilajit) in select cases, ensuring they complement—not replace—foundational metabolic and lifestyle changes (Gyllenhaal et al., 2000; Pan et al., 2008).

Reasoning:

• SHBG is a risk marker and regulator, not a problem to “fix” in isolation. Moving SHBG in the wrong direction can worsen cardiometabolic risk. Instead, aim to optimize free hormone exposure by correcting metabolic drivers and judiciously titrating hormones.

Integrative Chiropractic Care in SHBG Context:

• By improving autonomic balance through spinal and soft-tissue interventions, we enhance hepatic perfusion, gut motility, and sleep quality, thereby indirectly supporting metabolic regulation and SHBG homeostasis. My clinical observation is that patients receiving consistent integrative care maintain steadier free testosterone trajectories due to better adherence, improved sleep, and reduced systemic inflammation.

PCOS: Gut Dysbiosis, Insulin Resistance, and Androgen Dynamics

Key concept: The root drivers in many PCOS presentations include gut dysbiosis, insulin resistance, and chronic inflammation. Ovarian cysts are a phenotypic expression rather than the primary cause.

• Diagnosis:

• • Rotterdam criteria: Any two of the following—oligo/anovulation, hyperandrogenism, polycystic ovaries (Rotterdam ESHRE/ASRM, 2004).
  • Many patients present without obesity or cysts but maintain the phenotype of PCOS-like syndrome: acne, hirsutism, cycle irregularity, and infertility.

• Physiology:

• • Hyperinsulinemia stimulates ovarian theca cells to produce androgens and lowers SHBG, increasing free testosterone (Diamanti-Kandarakis & Dunaif, 2012).
  • Gut dysbiosis promotes endotoxemia and the release of inflammatory cytokines (e.g., via LPS/TLR4-driven cascades), thereby worsening insulin signaling and androgen production (Tremellen & Pearce, 2012).
  • An elevated LH: FSH ratio may indicate neuroendocrine stress on the hypothalamic-pituitary-ovarian axis, though the literature debates its reliability. Clinically, a reversed ratio can be suggestive but is not definitive.

• Treatment framework:

1. 1. Address gut integrity:

• Ensure regular bowel movements, fiber adequacy, and personalized diet transitions.
• Use a high-quality probiotic to support barrier function and immune modulation. In my practice, targeted multi-strain formulations have improved bloating, skin, and cycle regularity over months.

• • Treat insulin resistance:

• Metformin titration: start at 500 mg at night, add 500 mg increments as tolerated, aiming for 1,000 mg BID (extended-release preferred for GI tolerability) (Lord et al., 2003).
• GLP-1 receptor agonists (semaglutide, tirzepatide): potent tools for weight reduction, satiety, and improved glycemic control; consider when metformin is insufficient or not tolerated (Frias et al., 2021).

• • Manage androgenic symptoms:

• In PCOS, spironolactone 100 mg/day can reduce DHT-mediated hirsutism and acne, lower aldosterone levels, and modestly affect LH. For non-PCOS cosmetic hirsutism, I rarely exceed 50 mg/day to avoid overt antiandrogen effects.
• Topical antiandrogen options for acne can be used adjunctively.

• • Support fertility:

• PCOS patients are often progesterone-deficient; in pregnancy attempts, I target serum progesterone >20–24 ng/mL, frequently using 200 mg nightly, with daytime add-ons when needed (Conway et al., 2014).
• Optimize thyroid function (aim for euthyroid status; consider T4/T3 balance when indicated) to normalize ovulatory signaling.

• • Time horizon:

• Restoring ovulation and cycles frequently takes months to years. I counsel patients to expect gradual improvements and reinforce adherence through coaching and integrative visit structures.

• Dosing caution with testosterone in PCOS-like presentations:

• Start low. Due to lower SHBG and heightened hair follicle sensitivity, standard doses can trigger acne and hirsutism. I begin around 75–87.5 mg and titrate based on symptoms and free testosterone, adding gut and metabolic therapies first. It is safer to add later than to subtract too late.

Integrative Chiropractic Care in PCOS:

• Correcting biomechanical stress, enhancing vagal tone, and lowering sympathetic overdrive improve gut motility, sleep depth, and insulin sensitivity. In practice, PCOS patients receiving regular integrative sessions show better GI tolerance to metformin/GLP-1s, improved adherence to diet changes, and faster resolution of pain syndromes that otherwise derail lifestyle efforts. My clinical notes repeatedly record improved cycle regularity following combined spinal adjustments, diaphragmatic breathing coaching, and stress management plans.

PSA and Percent-Free PSA: Modern Interpretation in Men on TRT

Key concept: PSA alone is specific, but it has low sensitivity for malignancy, and ejaculation, prostate manipulation, BPH, and prostatitis influence it. Percent-free PSA improves sensitivity and risk stratification for biopsy decisions.

• Practical steps:
  • Order percent-free PSA reflexively whenever total PSA is above the threshold (labs can auto-reflex).
  • Interpret percent-free PSA:

• <10%: higher likelihood of prostate cancer—consider urology referral or prostate MRI.
• 10–25%: intermediate—evaluate symptoms; treat prostatitis if present; recheck.
• >25%: lower likelihood—monitor and re-evaluate as needed (AUA, 2023; Loeb et al., 2015).

• • Evaluate the velocity of change. A rapid increase (e.g., from 0.9 to 2.9 ng/mL within a year) is concerning even if the absolute value is modest.
  • Recognize confounders:

• Ejaculation, prostate massage, and vigorous cycling raise total PSA.
• Finasteride lowers PSA ~50%; double measured values for interpretation (Thompson et al., 2003).

• • Prefer prostate MRI over immediate biopsy when percent-free PSA suggests risk; MRI detects suspicious lesions and reads prostatitis/BPH, sparing unnecessary biopsies.
• TRT after prostate cancer:

• Contemporary guidance increasingly allows resumption of testosterone therapy after achieving a stable normal PSA, under shared decision-making and urologic oversight (Khera et al., 2015). I monitor PSA and percent-free PSA closely and prioritize MRI if there is any discordance between them.

Integrative Chiropractic Care in Men’s Health:

• Adjustments targeting pelvic biomechanics and lumbar-sacral movement can reduce pelvic floor tension, helping LUTS symptoms in BPH/prostatitis.
• Breathing and mobility routines reduce sympathetic tone, potentially easing lower urinary tract dysfunction and improving sleep—both of which are relevant to androgen balance and adherence to PSA monitoring.

DHEA: The Neurosteroid You May Be Missing

Key concept: DHEA is not just a precursor to testosterone; it acts as a potent steroid with its own receptors in the brain and nervous system, modulating mood, immune function, and vascular physiology (Maninger et al., 2009; Prough et al., 2016).

• Physiology:

• • Produced by the adrenal cortex, quickly sulfated to DHEA-S, which is more stable and is the preferred test.
  • Levels decline with age, paralleling declines in thyroid hormone conversion (deiodinase activity) and gonadal steroids, thereby affecting endothelial function, neuroprotection, bone, and immunity.
  • DHEA has immunomodulatory effects (enhancing NK cell function), supports endothelial health, and attenuates depression and cognitive decline in certain populations (Morales et al., 1994; Savineau et al., 2013).

• Clinical picture:

• • Patients with optimized thyroid and testosterone who still experience low libido, anxiety, depressed mood, or joint discomfort frequently show low DHEA-S.
  • Elevating DHEA-S often improves vitality, sexual function (via conversion to DHT, a key libido metabolite), and resilience to stress.

• Dosing:
  • I prefer pharmaceutical-grade compounded DHEA for consistency. Typical ranges:

• Women: 10–20 mg/day, adjusting based on symptoms and DHEA-S targets.
• Men: 25–50 mg/day, titrated carefully.

• • Over-the-counter products vary; if used, start low and monitor.
  • Watch for androgenic side effects (acne, hair changes) via DHT conversion; I avoid DHEA in women with active PCOS unless other pathways have stabilized.
• Lab targeting:

• Standard lab ranges are wide because they reflect the distributions of sick populations. I aim for upper-normal DHEA-S levels associated with better functional outcomes, around 100–200 ?g/dL in women and 200–400 ?g/dL in men, individualized by age and symptom response (Weber et al., 2013).

Integrative Chiropractic Care and DHEA:

• By reducing chronic sympathetic load through manual therapy, breath training, and postural interventions, we modulate cortisol-DHEA balance. I consistently see improved DHEA-S stability in patients who engage in regular integrative sessions and stress-reduction practices, particularly when paired with sleep hygiene and anti-inflammatory nutrition.

Vitamin D, Thyroid, and Oxygen Delivery: Receptor-Level Synergy

Key concept: Hormones act through receptors and transcriptional programs; nutrient status and oxygen availability change the amplitude of those signals.

• Vitamin D: Enhances nuclear receptor co-activation, immune modulation, and steroid receptor sensitivity (Bouillon et al., 2019). I aim for 25(OH)D levels in the 40–60 ng/mL range unless contraindicated, reassessing quarterly when initiating hormone adjustments.
• Thyroid: Suboptimal T3 at the tissue level blunts androgen receptor expression and metabolic throughput. I evaluate TSH, free T4, free T3, and often reverse T3, targeting a euthyroid state that aligns with symptom relief and objective measures.
• Oxygen delivery: Poor respiratory mechanics and low fitness reduce mitochondrial oxygen uptake and tissue oxygenation, dampening hormonal effects. Integrative care includes breathing practice, graded movement, and posture correction to optimize ventilatory efficiency.

Metformin and GLP-1s: Why They Work in PCOS and Metabolically Low SHBG States

• Metformin improves hepatic glucose output, enhances AMPK signaling, and lowers insulin, thereby reducing androgen drive and raising SHBG appropriately (Lord et al., 2003).
• GLP-1 agonists increase satiety, slow gastric emptying, and improve insulin dynamics, often normalizing cycles and reducing inflammatory acne/hirsutism over time (Frias et al., 2021).

Clinical Algorithm: Bringing It All Together

• Step 1: Assess symptoms and systems

• • History of cycles, fertility, acne/hirsutism, sleep, stress, bowels, diet, movement.
  • Labs: total and free testosterone, SHBG, DHEA-S, LH/FSH, fasting insulin, A1C, lipid profile, vitamin D, thyroid panel, CRP.

• Step 2: Identify terrain issues

• • Gut dysbiosis signs, insulin resistance, sleep disruption, and chronic pain/stress.

• Step 3: Initiate foundational supports

• • Diet fit to patient readiness, fiber/probiotics, sleep hygiene, breathing and movement routines, vitamin D repletion, thyroid optimization.

• Step 4: Targeted pharmacology

• • PCOS: Metformin titration, GLP-1s as indicated, spironolactone 100 mg/day for hirsutism/acne in PCOS, progesterone support for fertility, low-dose testosterone if needed with cautious titration.
  • Men’s TRT: Monitor PSA with percent-free; consider MRI when indicated; collaborate with urology; resume TRT post-stable normal PSA under supervision.

• Step 5: Monitor and adapt

• • Recheck labs at 8–12 weeks initially, then quarterly; track symptom changes; adjust doses gradually.

• Step 6: Integrative chiropractic care cadence

• • Regular sessions to support autonomic regulation, pain reduction, movement efficiency, and adherence. This improves outcomes and reduces medication side effects by stabilizing lifestyle variables.

Clinical Observations from My Practice

• Patients who consistently engage in integrative care achieve faster symptom relief, even when lab results are slow to change—especially in PCOS and DHEA optimization.
• Vitamin D repletion is the most leveraged low-cost intervention to improve receptor sensitivity; patients with borderline levels often experience outsized improvements with consistent dosing.
• Percent-free PSA saved multiple patients from unnecessary biopsies; MRI clarified prostatitis vs. suspicious lesions, allowing sustained TRT with appropriate monitoring.

Key Takeaways

• Treat hormone symptoms as expressions of a system—not isolated molecules.
• SHBG is an important health marker; do not reflexively lower it. Address metabolic terrain and titrate hormones patiently.
• PCOS care is effective when you prioritize gut dysbiosis, insulin resistance, and progesterone/thyroid balance; androgens are managed with conservative dosing and antiandrogen support.
• In men, pair PSA with percent-free PSA and use MRI to refine decisions.
• DHEA is a neurosteroid with broad effects; check and optimize DHEA-S
• Integrative chiropractic care strengthens autonomic balance, pain resilience, and adherence—raising the ceiling for every endocrine intervention.

References

• AUA 2023 Early Detection of Prostate Cancer Guideline (American Urological Association, 2023).
• Bolland, M. J., Grey, A., & Reid, I. R. (2014). Vitamin D supplementation and musculoskeletal health. Lancet Diabetes & Endocrinology, 2(5), 363–382.
• Bouillon, R., Marcocci, C., Carmeliet, G., et al. (2019). Skeletal and extraskeletal actions of vitamin D: Current evidence and outstanding questions. Endocrine Reviews, 40(4), 1109–1151.
• Crawford, C., Kapoor, S., & Dobs, A. (2019). SHBG and metabolic syndrome: Clinical correlations. Journal of Clinical Endocrinology & Metabolism, 104(12), 5850–5860.
• Diamanti-Kandarakis, E., & Dunaif, A. (2012). Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocrine Reviews, 33(6), 981–1030.
• Ding, E. L., Song, Y., Manson, J. E., et al. (2009). Sex hormone-binding globulin and risk of type 2 diabetes in women and men. New England Journal of Medicine, 361(12), 1152–1163.
• Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in type 2 diabetes. New England Journal of Medicine, 385(6), 503–515.
• Gyllenhaal, C., Merritt, S., Peterson, S., et al. (2000). Shilajit: A review of contemporary and traditional uses. Journal of Ethnopharmacology, 73(1–2), 153–160.
• Khera, M., Bhattacharya, R. K., Blick, G., et al. (2015). Testosterone therapy in men with treated and untreated prostate cancer: Impact on oncologic outcomes. Journal of Urology, 194(5), 1271–1276.
• Loeb, S., Carter, H. B., et al. (2015). PSA and percent free PSA in prostate cancer detection. Urology Clinics of North America, 42(3), 223–229.
• Lord, J., Thomas, R., Fox, B., et al. (2003). Metformin in polycystic ovary syndrome: Systematic review and meta-analysis. BMJ, 327(7421), 951.
• Maninger, N., Wolkowitz, O. M., Reus, V. I., et al. (2009). Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate. Frontiers in Neuroendocrinology, 30(1), 65–91.
• Morales, A. J., Nolan, J. J., Nelson, J. C., & Yen, S. S. (1994). Effects of DHEA in men and women. Clinical Endocrinology, 43(4), 501–508.
• Pan, M. H., Zhou, Y., & Chen, C. J. (2008). DIM and hormone metabolism: Mechanisms and clinical prospects. Molecular Nutrition & Food Research, 52(1), 101–113.
• Prough, R. A., Clark, B. J., & Klinge, C. M. (2016). DHEA and DHEA-S signaling pathways. Steroids, 111, 54–61.
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to PCOS. Human Reproduction, 19(1), 41–47.
• Savineau, J. P., et al. (2013). Vascular effects of DHEA. European Journal of Pharmacology, 713(1–3), 16–24.
• Thompson, I. M., Goodman, P. J., Tangen, C. M., et al. (2003). The influence of finasteride on PSA. Journal of the National Cancer Institute, 95(13), 972–979.
• Weber, M. T., Mapstone, M., & Maki, P. M. (2013). DHEA-S and cognitive aging. Endocrine, 43(1), 59–63.

SEO tags: PCOS treatment, SHBG high low management, percent free PSA interpretation, DHEA neurosteroid benefits, metformin titration PCOS, GLP-1 semaglutide tirzepatide PCOS, spironolactone dosing hirsutism, testosterone therapy after prostate cancer, integrative chiropractic care hormones, vitamin D receptor hormone sensitivity, thyroid optimization and androgens, gut dysbiosis and insulin resistance, androgen receptor physiology, evidence-based hormone therapy, Dr. Alexander Jimenez DC APRN FNP-BC